No description available.

We describe an 11 year old girl with a de novo unbalanced t(X;10) that resulted in a deletion of Xq26→Xqter and a trisomy of 10q21→10qter. Her clinical features were of distal trisomy 10q, but she lacked the cardiovascular and renal malformations observed in duplications of 10q24→10qter and had only moderate mental retardation. X inactivation was assessed on peripheral blood lymphocytes by late replication with BrdU (LR) and the human androgen receptor assay (HAR). By LR the der(X) was inactive without spreading to 10q21→10qter in all cells. The HAR assay showed skewed methylation of the paternal allele (90%). The correlation of HAR and LR suggests that the der(X) was paternally inherited and is consistent with data from other de novo balanced and unbalanced X;autosome translocations detected in females. This is the first report of parental origin of a de novo trisomy 10q.

No description available.

Prostate cancer is the most commonly diagnosed non-skin cancer in men and the second leading cause of cancer death in the United States. Prostate cancer, like many cancers, is a disease that generally requires a long period of time to develop and grow before it becomes detectable. This long period of latency makes prostate cancer a candidate for dietary chemoprevention. Soy and selenium (Se), are associated with a decreased risk of prostate cancer. We previously showed that high dietary intake of selenium (Se) and soy isoflavones decreased the expression of the androgen receptor (AR) and AR-regulated genes in the prostates of healthy rats. In this study we hypothesized that the downregulation of AR and AR-regulated genes would inhibit tumorigenesis in the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse. Mice were fed one of two stock diets with or without a supplement of Se in a 2 X 2 factorial design. The stock diets provided high or low dietary isoflavones. Mice were exposed to the diets from conception and sacrificed at 18 or 24 weeks of age. Prostate histopathology, urogenital tract (UGT) weight, serum IGF-1 levels, and the expression of AR and AR-regulated genes in the dorsolateral prostate was examined using quantitative PCR and Western blotting. Urogenital tract (UGT) weight was reduced compared to control in all dietary groups containing high Se, isoflavones, or both at 24 weeks (p<0.005). Dietary isoflavones delayed tumor progression and downregulated protein levels of AR, AR-regulated genes, and upregulated the protective FOXO1 and FOXO3a transcription factors. High dietary isoflavones also decreased the phosphorylation of the IGF-1R. The only main effect of Se was the upregulation of AKR1C14 the enzyme that deactivates 5&aplha;-DHT.This study identifies a previously unknown effect of isoflavones in the upregulation of FOXO expression and confirms previous studies of isoflavones' anticancer effects. Further research is needed to find a protective dose or form of Se and to elucidate the mechanism of isoflavones.

Prostate cancer is the second most commonly occurring cancer in men in the United States. Generally, an extended period of time is needed for a mutation to develop into a full scale tumor. Because of this long latency period, lifestyle and environmental factors, such as diet, may play an important role in the development and progression of the disease. Diet is one factor that has been implicated in the risk for developing prostate cancer. We previously showed that diets high in soy isoflavones and selenium (Se) decreased androgen receptor expression and expression of androgen regulated genes in healthy rat prostates. The purpose of this study was to determine whether treatment of soy isoflavones and/or supplemental Se provide chemopreventive effects in the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) model of prostate cancer, and whether the timing of the introduction of these nutrients determines protective effects. Male hemizygous C57/BL6 x FVB TRAMP mice were exposed to a diet high in isoflavones, a 4 mg/kg daily bolus of supplemental Se as methylselenocysteine (MSC), or the combination of high isoflavones and MSC starting at one of two time points: conception or 6 weeks of age, and were killed and dissected for prostate tissue, liver, and serum at either 4 weeks or 12 weeks of age (n per dietary treatment = 20: total mice = 240). Treatment with MSC resulted in decreased urogenital tract weight at 4 and 12 weeks. Treatment with MSC and isoflavones, both individually and as a combination, resulted in decreased androgen receptor expression, 5 alpha-reductase levels, and aromatase levels. The combination of MSC and a basal diet high in isoflavones resulted in decreased serum IGF-1 levels in 12 week TRAMP mice. Treatment from conception resulted in greater decreases in urogenital tract weight, 5 alpha-reductase expression, and aromatase expression than treatment from 6 weeks. This study demonstrated that in 12 week TRAMP mice, reductions in risk factors for prostate cancer by treatments of high isoflavones and supplemental Se are maximized by introduction to treatments at conception.

京都大学 / 新制・論文博士 / 博士(医学) / 乙第13517号 / 論医博第2267号 / 新制||医||1061(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 遊佐 宏介, 教授 戸井 雅和, 教授 小川 誠司 / 学位規則第4条第2項該当 / Doctor of Medical Science / Kyoto University / DFAM

Androgens are the main regulators of human hair growth stimulating larger, terminal hair development e.g. beard and causing scalp balding, androgenetic alopecia. Hair disorders cause psychological distress but are poorly controlled. Androgens probably act by altering regulatory paracrine factors produced by the mesenchyme-derived dermal papilla. This study aimed to investigate paracrine factors involved in androgen-regulated alopecia, particularly hepatocyte growth factor (HGF) family members, by investigating their in vivo status. Balding and non-balding scalp hair follicles and their component tissues were isolated and analysed by molecular biological methods (reverse transcriptase-polymerase chain reaction (RT-PCR), quantitative PCR and DNA microarray analysis), cell culture and immunohistochemistry. Scalp follicles expressed a range of paracrine messenger genes. The dermal papilla, cultured dermal papilla cells and dermal sheath expressed several HGF family genes, while matrix cells only produced the receptor RON suggesting autocrine roles for HGF and MSP, but a paracrine route only for MSP. Comparing balding and non-balding follicles from the same individuals revealed the expected reduction in several keratin and keratin-related protein genes supporting this approach's validity. There were also significant differences in paracrine factors previously implicated in androgen action by in vitro studies. Several factors believed to increase during androgen stimulation of larger, darker follicles, e.g. IGF-I and SCF, were lowered in balding follicles, while putative inhibitory factors, e.g. TGFß-1, were increased. HGF and MSP and their receptors, c-Met and RON, were significantly reduced. These results increase our understanding of androgen action in human hair follicles; this could lead to better treatments for hair disorders. / Saudi government

A major problem in prostate cancer (PCa) management is the development of drug resistance. It is known that there are changes in PCa biology upon prolonged treatment with drugs, including anti-androgen drugs that alter cellular signaling processes leading to the development of castration resistant PCa. MicroRNAs (miRNAs) are regulatory molecules that modulate gene expression through inhibition of protein translation and modulate cellular functions. Altered expression of miRNAs is often noted in drug resistant cancer including PCa. Studies from our laboratory have identified a number of down-regulated miRNAs in PCa, including miR-l 7-92a miRNAs. Frabin (FGD4) is a target of the miR-l 7-92a cluster that was found to be up-regulated in PCa cells. For this paper’s investigation, an FGD4 knockdown approach was used to identify the effects on cell viability, cell cycle progression, cell migration and drug sensitivity. Two PCa cells lines, LNCaP-104S (androgen sensitive) and PC-3 (androgen independent), were used for our studies. MTS assays for both cell lines showed significant reduction in cell viability following knockdown of FGD4 compared to transfection with control siRNAs. Cell cycle analysis revealed an arrest in the G2/M phase of the cells that were transfected with FGD4 siRNAs. Cell migration assays revealed a decrease in migration rate of PC-3 cells after knockdown, which supports the involvement of FGD4 in actin- cytoskeleton rearrangement. Treatments with anti-mitotic drug Docetaxel (PC-3) or androgen receptor antagonist bicalutamide/Casodex (LNCaP-104S) showed improved sensitivity of the FGD4 siRNA treated cells to these drugs. Our results suggest the potential for FGD4 knockdown to be used in combination with currently used drugs, increasing the effectiveness of frontline chemotherapeutics.

No description available.

No description available.